Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Livzon Pharmaceutical Group ( (HK:1513) ) is now available.
Livzon Pharmaceutical Group announced that 194 of its products have been included in the 2025 National Reimbursement Drug List (NRDL) in China, which is expected to enhance market reach and drug accessibility. This inclusion is anticipated to positively impact the company’s future performance, although it will not materially affect current operations.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$37.23 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. operates in the pharmaceutical industry, focusing on the development, production, and sale of a wide range of pharmaceutical products. The company is known for its innovative drug formulations and has a significant market presence in China.
YTD Price Performance: 17.48%
Average Trading Volume: 866,231
Technical Sentiment Signal: Buy
Current Market Cap: HK$33.15B
Learn more about 1513 stock on TipRanks’ Stock Analysis page.